X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Companies signed a memorandum of understanding, for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum.
Lead Product(s): RNA-based Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: OliX Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET, DCBY02 to DynamiCure Biotechnology for use in its clinical trial.
Lead Product(s): DCBY02
Therapeutic Area: Oncology Product Name: DCBY02
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: ImaginAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 15, 2022
Details:
In pre-clinical studies, DCBY02 demonstrated the ability to bind to CD93, normalizing tumor vasculature, reducing hypoxia, and turning the tumor microenvironment (TME) from immunosuppressive to immunostimulatory.
Lead Product(s): DCBY02
Therapeutic Area: Oncology Product Name: DCBY02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase 1 clinical study.
Lead Product(s): DCBY02
Therapeutic Area: Oncology Product Name: DCBY02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
